International Journal of Hematology

, Volume 96, Issue 4, pp 521–524

Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon

  • Zaher K. Otrock
  • Rami A. Mahfouz
  • Zahera Fahed
  • Fadi S. Farhat
  • Azzam Ziade
  • Fadi Nasr
  • Nader Kassem
  • Miguel R. Abboud
Letter to the Editor

DOI: 10.1007/s12185-012-1168-9

Cite this article as:
Otrock, Z.K., Mahfouz, R.A., Fahed, Z. et al. Int J Hematol (2012) 96: 521. doi:10.1007/s12185-012-1168-9
  • 183 Downloads

Copyright information

© The Japanese Society of Hematology 2012

Authors and Affiliations

  • Zaher K. Otrock
    • 1
    • 7
  • Rami A. Mahfouz
    • 9
  • Zahera Fahed
    • 2
  • Fadi S. Farhat
    • 3
  • Azzam Ziade
    • 4
  • Fadi Nasr
    • 5
  • Nader Kassem
    • 6
  • Miguel R. Abboud
    • 8
  1. 1.Division of Hematology-Oncology, Department of Internal MedicineAmerican University of Beirut Medical CenterBeirutLebanon
  2. 2.Saint Louis HospitalDamascusSyria
  3. 3.Hammoud Hospital University Medical CenterBeirutLebanon
  4. 4.Rafic Hariri University HospitalBeirutLebanon
  5. 5.Hôtel-Dieu de France University HospitalBeirutLebanon
  6. 6.Al-Rasoul Al-Aazam HospitalBeirutLebanon
  7. 7.Department of Cardiovascular MedicineCleveland Clinic FoundationClevelandUSA
  8. 8.Department of PediatricsAmerican University of Beirut Medical CenterBeirutLebanon
  9. 9.Department of Pathology and Laboratory MedicineAmerican University of Beirut Medical CenterBeirutLebanon

Personalised recommendations